2. Academic Validation
  3. RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer

RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer

  • Expert Opin Ther Targets. 2020 Jan;24(1):1-5. doi: 10.1080/14728222.2020.1709824.
My-My Huynh 1,  Aarthi Jayanthan 1,  Mary Rose Pambid 1,  Gerrit Los 2,  Sandra E Dunn 1 2
Affiliations

Affiliations

  • 1 Phoenix Molecular Designs, Vancouver, British Columbia, Canada.
  • 2 Phoenix Molecular Designs, San Diego, CA, USA.
PMID: 31875730 DOI: 10.1080/14728222.2020.1709824
Keywords

Kinase inhibitors; RSK2; targeted therapy; triple-negative breast cancer (TNBC).

Figures
Products